OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Clinical trials for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Drug cocktail shows promise in slowing return of tough cancers
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, in 155 people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer had come back. The goal was to see if the combo was safe and worked better than olaparib alone at slowing cancer growth.…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC